The Phase III trial findings (NCT02125461) demonstrated that durvalumab, a PD-L1 inhibitor, has established itself as the preferred standard of care for patients with unresectable stage III NSCLC, who do not show any disease progression following chemoradiotherapy [290]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.